Lindbrook Capital’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | $72.6K | Buy |
482
+322
| +201% | +$48.5K | 0.01% | 824 |
|
|
2024
Q4 | $29.5K | Sell |
160
-4
| -2% | -$738 | ﹤0.01% | 1061 |
|
|
2024
Q3 | $32.3K | Buy |
164
+50
| +44% | +$9.85K | ﹤0.01% | 1026 |
|
|
2024
Q2 | $23.6K | Hold |
114
| – | – | ﹤0.01% | 1152 |
|
|
2024
Q1 | $30.9K | Buy |
114
+4
| +4% | +$1.08K | ﹤0.01% | 993 |
|
|
2023
Q4 | $26K | Buy |
110
+26
| +31% | +$6.15K | ﹤0.01% | 1044 |
|
|
2023
Q3 | $16.5K | Sell |
84
-48
| -36% | -$9.41K | ﹤0.01% | 1156 |
|
|
2023
Q2 | $27.8K | Buy |
132
+65
| +97% | +$13.7K | ﹤0.01% | 932 |
|
|
2023
Q1 | $13.5K | Sell |
67
-13
| -16% | -$2.62K | ﹤0.01% | 1267 |
|
|
2022
Q4 | $17.4K | Sell |
80
-41
| -34% | -$8.93K | ﹤0.01% | 1133 |
|
|
2022
Q3 | $24K | Buy |
121
+40
| +49% | +$7.93K | ﹤0.01% | 906 |
|
|
2022
Q2 | $17K | Buy |
81
+9
| +13% | +$1.89K | ﹤0.01% | 1030 |
|
|
2022
Q1 | $20K | Sell |
72
-13
| -15% | -$3.61K | ﹤0.01% | 996 |
|
|
2021
Q4 | $32K | Sell |
85
-8
| -9% | -$3.01K | ﹤0.01% | 861 |
|
|
2021
Q3 | $38K | Sell |
93
-5
| -5% | -$2.04K | 0.01% | 520 |
|
|
2021
Q2 | $36K | Buy |
98
+10
| +11% | +$3.67K | 0.01% | 572 |
|
|
2021
Q1 | $26K | Buy |
88
+15
| +21% | +$4.43K | 0.01% | 651 |
|
|
2020
Q4 | $18K | Buy |
73
+3
| +4% | +$740 | ﹤0.01% | 713 |
|
|
2020
Q3 | $16K | Buy |
70
+3
| +4% | +$686 | ﹤0.01% | 686 |
|
|
2020
Q2 | $12K | Sell |
67
-17
| -20% | -$3.05K | ﹤0.01% | 766 |
|
|
2020
Q1 | $11K | Buy |
84
+8
| +11% | +$1.05K | ﹤0.01% | 718 |
|
|
2019
Q4 | $12K | Hold |
76
| – | – | ﹤0.01% | 870 |
|
|
2019
Q3 | $10K | Buy |
76
+17
| +29% | +$2.24K | ﹤0.01% | 895 |
|
|
2019
Q2 | $8K | Hold |
59
| – | – | ﹤0.01% | 943 |
|
|
2019
Q1 | $8K | Hold |
59
| – | – | ﹤0.01% | 943 |
|
|
2018
Q4 | $6K | Buy |
+59
| New | +$6K | ﹤0.01% | 952 |
|